Dr. David L. Barker currently serves on the Boards of Directors of AmideBio and Singular Genomics Systems, and is Board Member and Chairman at Integrated Diagnostics and BioNano Genomics.
He is a scientific advisor to MiNDERA Corp. and Luna DNA. He was Vice President and Chief Scientific Officer at Illumina, Inc., from 2000 to 2007, and on the Illumina scientific advisory board through 2015. He was previously on the Boards of NextBio, which was acquired by Illumina in 2013, ProteinSimple, which was acquired by Bio-Techne in 2014, Zephyrus Biosciences, Inc., which was acquired by Bio-Techne in 2016, and IntegenX, which was acquired by Thermo Fisher Scientific in 2018.
Dr. Barker is a board member of the non-profit foundation Summit for Stem Cell, which supports research toward an autologous dopamine neuron replacement therapy for Parkinson’s disease.
Dr. Barker served from 1998 to 2000 as Vice President and Chief Science Advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham.
In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a PhD in Biochemistry from Brandeis University.